Journals / Kocatepe Tıp Dergisi / 2017 / Cilt: 18 - Sayı: 2

HEPATOSELLÜLER KARSİNOM HÜCRELERİNDE KARMOFURUN SİTOTOKSİK VE APOPTOTİK ETKİLERİ

Pages
55–60
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Özet

ÖZ

🔖

Cite This Article

KUŞ, G. (2017). HEPATOSELLÜLER KARSİNOM HÜCRELERİNDE KARMOFURUN SİTOTOKSİK VE APOPTOTİK ETKİLERİ. Kocatepe Tıp Dergisi, Cilt: 18 - Sayı: 2, 55–60. https://ajindex.com/articles/201211

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. KAYNAKLAR Günay Y, Güler N, Akyıldız M ve ark. Hepatosellüler karsinoma ve canlı vericili karaciğer nakli:kanser nüksü ve hasta sağkalımını etkileyen faktörler. Tek merkez deneyimi. Gaziantep Tıp Dergisi 2013;19(3):173-9.
  2. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitontreatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43(3):425-34.
  3. Balkan BM, Sel T. Vitamin C’nin HepG2 hücrelerinde apoptozis üzerine etkileri. Ankara Üniversitesi Veteriner Fakültesi Dergisi 2014;61:237-41.
  4. Reynolds CP, Maurera, BJ, Kolesnick RN. Ceramide synthesisand metabolism as a target for cancer therapy. Cancer Lett 2004;206:169–80. Albi E and Mgni MV. Sphingolipid metabolism inhibitors andcell function. The Open Enzyme Inhibition Journal 2008;1,72-9.
  5. Beckham TH, Elojeimy S, Cheng JC, et al. Targetingsphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets. 2010;14:529-39.
  6. Chalfant CE, Rathman K, Pinkerman RL and et al. De novoceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002;277,12587-95.
  7. Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta 2008;1781:424-34.
  8. Strelow A, Bernardo K, Klages SA, et al. Overexpression ofacid ceramidase protects from tumor necrosis factor induced cell death. J Exp Med 2000;192:601-11. Kolesnick R. The therapeutic potential of modulating theceramide/sphingomyelin pathway, J Clin Invest 2000;110:3–8.
  9. Liu X, Cheng JC, Turner LS, et al. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 2009;13:1449-1458.
  10. Mahdy AEM, Cheng JC, Li Jun. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation:AC inhibition, a potential radiosensitizier. Mol Ther 2009;17:430-8.
  11. Huerta S, Gaulet EJ, Huerta-Yepez S, Livingston EH. Screening and detection of apoptosis. J Surg Res 2007;139:143–56
  12. Engedal N, Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 2001;46:289-97
  13. Realini N, Solorzano C, Pagliuca C, et al. Discovery ofhighly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Scientific Reports 2013;3:1-7.
  14. Hu W, Xu R, Sun W, et al. Alk